Tags

Type your tag names separated by a space and hit enter

Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Gynecol Oncol. 2008 Jan; 108(1):136-40.GO

Abstract

OBJECTIVE

To evaluate the clinicopathological prognostic factors and outcome of chemotherapy in ovarian carcinosarcomas.

METHODS

We reviewed the records of 26 patients treated from 1990 to 2006 at the Oncology Institute of Istanbul University. Clinical data including demographics, stage, surgery, chemotherapy, and survival were collected from patients' charts.

RESULTS

All patients underwent initial debulking surgery. Optimal debulking was achieved in 21 (81%) patients. The most striking clinicopathological finding was the high incidence of hemorrhagic ascites (n: 6) which was observed in 60% of the patients with ascites (n: 10). The overall median survival of the patients was 26 months. Residual disease was associated with a decreased overall survival, P=0.04. Median survival (50 months vs 9.7 months, P=0.042) of the patients with early stage disease were longer than the patients with advanced stage. Twenty-two patients received platinum-based combination chemotherapy. There was a trend for increased median survival in the patients who were treated with carboplatin/paclitaxel combination (P=0.066). Although the numbers were insufficient for statistical evaluation, the patients treated with ifosfamide combinations had improved survival (36 months vs 26 months). However, when the patients treated with ifosfamide and carboplatin/paclitaxel combinations were combined, survival was statistically improved compared to the other regimens (36 months vs 9.7 months, P=0.04). Chemotherapy regimens containing doxorubicin or cyclophosphamide were not encouraging. Stage (P=0.02) and adjuvant platinum-based chemotherapy containing either paclitaxel or ifosfamide (P=0.024) remained predictive of outcome in the multivariate analysis.

CONCLUSIONS

Hemorrhagic ascites can be used in the initial differential diagnosis of ovarian carcinosarcomas. Stage, optimal debulking and type of adjuvant therapy were statistically significant prognostic predictors of ovarian carcinosarcomas. We advise that patients with ovarian carcinosarcomas should be treated by optimal cytoreduction followed by adjuvant platinum/taxan or platinum/ifosfamide combinations.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Cicin I
Department of Medical Oncology, Faculty of Medicine, Trakya University, Turkey. irfancicin@hotmail.com
Saip P
No affiliation info available
Eralp Y
No affiliation info available
Selam M
No affiliation info available
Topuz S
No affiliation info available
Ozluk Y
No affiliation info available
Aydin Y
No affiliation info available
Topuz E
No affiliation info available

MeSH

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinosarcomaCisplatinCyclophosphamideDoxorubicinEtoposideFallopian Tube NeoplasmsFemaleHumansMiddle AgedNeoplasm StagingOvarian NeoplasmsPaclitaxelPeritoneal NeoplasmsPrognosisRetrospective StudiesSurvival Rate

Pub Type(s)

Journal Article

Language

eng

PubMed ID

17936342

Clinical Trial Links

Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)

Citation

Cicin, Irfan, et al. "Ovarian Carcinosarcomas: Clinicopathological Prognostic Factors and Evaluation of Chemotherapy Regimens Containing Platinum." Gynecologic Oncology, vol. 108, no. 1, 2008, pp. 136-40.
Cicin I, Saip P, Eralp Y, et al. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol. 2008;108(1):136-40.
Cicin, I., Saip, P., Eralp, Y., Selam, M., Topuz, S., Ozluk, Y., Aydin, Y., & Topuz, E. (2008). Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecologic Oncology, 108(1), 136-40.
Cicin I, et al. Ovarian Carcinosarcomas: Clinicopathological Prognostic Factors and Evaluation of Chemotherapy Regimens Containing Platinum. Gynecol Oncol. 2008;108(1):136-40. PubMed PMID: 17936342.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. AU - Cicin,Irfan, AU - Saip,Pinar, AU - Eralp,Yesim, AU - Selam,Meltem, AU - Topuz,Samet, AU - Ozluk,Yasemin, AU - Aydin,Yucel, AU - Topuz,Erkan, Y1 - 2007/10/23/ PY - 2007/07/12/received PY - 2007/08/27/revised PY - 2007/09/04/accepted PY - 2007/10/16/pubmed PY - 2008/1/16/medline PY - 2007/10/16/entrez SP - 136 EP - 40 JF - Gynecologic oncology JO - Gynecol Oncol VL - 108 IS - 1 N2 - OBJECTIVE: To evaluate the clinicopathological prognostic factors and outcome of chemotherapy in ovarian carcinosarcomas. METHODS: We reviewed the records of 26 patients treated from 1990 to 2006 at the Oncology Institute of Istanbul University. Clinical data including demographics, stage, surgery, chemotherapy, and survival were collected from patients' charts. RESULTS: All patients underwent initial debulking surgery. Optimal debulking was achieved in 21 (81%) patients. The most striking clinicopathological finding was the high incidence of hemorrhagic ascites (n: 6) which was observed in 60% of the patients with ascites (n: 10). The overall median survival of the patients was 26 months. Residual disease was associated with a decreased overall survival, P=0.04. Median survival (50 months vs 9.7 months, P=0.042) of the patients with early stage disease were longer than the patients with advanced stage. Twenty-two patients received platinum-based combination chemotherapy. There was a trend for increased median survival in the patients who were treated with carboplatin/paclitaxel combination (P=0.066). Although the numbers were insufficient for statistical evaluation, the patients treated with ifosfamide combinations had improved survival (36 months vs 26 months). However, when the patients treated with ifosfamide and carboplatin/paclitaxel combinations were combined, survival was statistically improved compared to the other regimens (36 months vs 9.7 months, P=0.04). Chemotherapy regimens containing doxorubicin or cyclophosphamide were not encouraging. Stage (P=0.02) and adjuvant platinum-based chemotherapy containing either paclitaxel or ifosfamide (P=0.024) remained predictive of outcome in the multivariate analysis. CONCLUSIONS: Hemorrhagic ascites can be used in the initial differential diagnosis of ovarian carcinosarcomas. Stage, optimal debulking and type of adjuvant therapy were statistically significant prognostic predictors of ovarian carcinosarcomas. We advise that patients with ovarian carcinosarcomas should be treated by optimal cytoreduction followed by adjuvant platinum/taxan or platinum/ifosfamide combinations. SN - 1095-6859 UR - https://www.unboundmedicine.com/medline/citation/17936342/Ovarian_carcinosarcomas:_clinicopathological_prognostic_factors_and_evaluation_of_chemotherapy_regimens_containing_platinum_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0090-8258(07)00723-8 DB - PRIME DP - Unbound Medicine ER -